JUBLPHARMA / NSE / Biotechnology & Drugs
Jubilant Pharmova
1Y Price Trend
Key Information
Recommendations
RatingStrong Buy
Target High1,250
Target Low783.75
Target Mean1.75
Target Median93.75
Risk Metrics
Overall RiskBalanced risk
Board Risk29.9
Key Analysis
Overall score, performance score, return rating, defensive, aggressive, and balanced views.
Download appProjection Analytics
Best-case, base-case, worst-case, and dynamic AI projection views.
Download appLatest stock news
Tax Setback for Jubilant Generics as Department Orders Rs 107.89 Cr Adjustment Medical Dialogues
Ashish Mukkirwar appointed CFO of Jubilant Pharmova Indian Pharma Post
Jubilant Pharmova re-appoints MDs for three years scanx.trade
Jubilant Pharmova Ltd is Rated Sell Markets Mojo
Jubilant Pharmo Consolidated March 2026 Net Sales at Rs 2,290.00 crore, up 18.73% Y-o-Y Moneycontrol.com
Jubilant Pharmo Standalone March 2026 Net Sales at Rs 70.30 crore, down 67.65% Y-o-Y Moneycontrol.com
Ashish Mukkirwar Appointed as Chief Financial Officer at Jubilant Pharmova Limited hrtoday.in
Jubilant Pharmova FY26 revenue rises 14%; PAT grows 7% scanx.trade
© SharekeyX | Rusaka Technologies 2024-2026